Alpha Wave Global, LP bought ANRO

February 6, 2024 · Form 4 insider transaction

Alpha Wave Global, LP bought 1,962,995 shares of Alto Neuroscience, Inc., a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Acquired (buy-side)
Shares
1,962,995
Price
N/A
Total value
N/A
Role
SecurityCommon Stock
Transaction codeC: Conversion of a derivative
Transaction dateFebruary 6, 2024
Filing dateFebruary 8, 2024
Shares owned after1,962,995
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of common stock on a 2.1226069 for 1 basis into the number of shares of common stock shown in column 3 and had no expiration date.; Securities held by Alpha Wave Ventures II, LP ("Alpha Wave Ventures"). Alpha Wave Ventures GP, Ltd ("Alpha Wave Ventures GP") is the general partner of Alpha Wave Ventures. Alpha Wave Ventures GP is a joint venture between Alpha Wave Global, LP ("Alpha Wave") and Lunate Holding RSC LTD ("Lunate"). Lunate is a subsidiary of Chimera Investment LLC ("Chimera," together with Alpha Wave Ventures GP, Alpha Wave and Lunate, the "Reporting Persons"). Richard Gerson is the Chairman and Chief Investment Officer of Alpha Wave. Chimera is controlled by its board of directors.; For purposes of Section 16 of the Securities Exchange Act of 1934, each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of the Reporting Persons is the beneficial owner of such securities for purposes of Section 16 or any other purpose.

View the original Form 4 on SEC EDGAR